CASE COMMENTS : UNILATERAL PRACTICES – HEALTHCARE - MARKET DEFINITION – DOMINANCE – ABUSIVE USE OF THE PROCEDURES RELATED TO SUPPLEMENTARY PROTECTION CERTIFICATES AND OF THE PROCEDURE FOR MARKETING PHARMACEUTICAL PRODUCTS – DECEPTION – EFFECTS OF THE PRACTICES

Market definition - Abusive use of regulatory procedures: The Court of Justice sanctions definitively the abusive use of regulatory procedures to prevent or delay the arrival of generic drugs on the market (AstraZeneca)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. CJEU, 6 December 2012, AstraZeneca AB and AstraZeneca plc v Commission, C-457/10 P The judgment of the Court of Justice of 6 December 2012 brings to a close the judicial saga relating to the decision of the European Commission (the "Commission") which for the first time sanctioned the misuse by an originator company of regulatory procedures in the pharmaceutical sector to prevent or delay the arrival of generics on the market. This case is well known. In its decision of 15 June 2005 concerning AstraZeneca (Commission, 15 June 2005, AstraZeneca, case 37.507), the Commission imposed a fine of €60 million for two abuses of dominant position on the market for

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Anne Wachsmann, Nicolas Zacharie, Market definition - Abusive use of regulatory procedures: The Court of Justice sanctions definitively the abusive use of regulatory procedures to prevent or delay the arrival of generic drugs on the market (AstraZeneca), 6 December 2012, Concurrences N° 1-2013, Art. N° 50455, pp. 78-81

Visites 576

All reviews